Alnylam announces retirement of steven paul, m.d. from board of directors

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, announced that steven paul, m.d. is retiring from the board of directors effective april 16, 2022. dr. paul has served as a member of the alnylam board of directors since september 2010. he brought to the board more than 25 years of management experience in the pharmaceutical industry and 35 years of scientific research experience during his time of service. he is widely recog
ALNY Ratings Summary
ALNY Quant Ranking